Canacinumab Other names: Canakinumab

Therapeutic indications

Canacinumab is indicated for:

Cryopyrin associated periodic syndromes (CAPS)

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Canakinumab is indicated for the treatment of cryopyrin-associated periodic syndromes (CAPS) including:

Muckle-Wells syndrome (MWS),
Neonatal-onset multisystem inflammatory disease (NOMID)/chronic infantile neurological, cutaneous, articular syndrome (CINCA),
Severe forms of familial cold autoinflammatory syndrome (FCAS)/familial cold urticaria (FCU) presenting with signs and symptoms beyond cold-induced urticarial skin rash.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

2-4 mg/kg once every 8 weeks

Tumour necrosis factor receptor associated periodic syndrome (TRAPS)

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Canakinumab is indicated for the treatment of tumour necrosis factor (TNF) receptor associated periodic syndrome (TRAPS).

For this indication, competent medicine agencies globally authorize below treatments (click for details):

2-4 mg/kg once every 4 weeks

Hyperimmunoglobulin D syndrome (HIDS), mevalonate kinase deficiency (MKD)

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Canakinumab is indicated for the treatment of hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD).

For this indication, competent medicine agencies globally authorize below treatments (click for details):

2-4 mg/kg once every 4 weeks

Familial Mediterranean fever (FMF)

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Canakinumab is indicated for the treatment of Familial Mediterranean Fever (FMF). Canakinumab should be given in combination with colchicine, if appropriate.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

2-4 mg/kg once every 4 weeks

Still's disease

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Canakinumab is indicated for the treatment of active Still’s disease including adult-onset Still’s disease (AOSD) and systemic juvenile idiopathic arthritis (SJIA) in patients aged 2 years and older who have responded inadequately to previous therapy with non-steroidal anti-inflammatory drugs (NSAIDs) and systemic corticosteroids. Canakinumab can be given as monotherapy or in combination with methotrexate.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

4 mg/kg once every 4 weeks

Gouty arthritis

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Canakinumab is indicated for the symptomatic treatment of adult patients with frequent gouty arthritis attacks (at least 3 attacks in the previous 12 months) in whom non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

150 mg once

Contraindications

Canacinumab is contraindicated in the following cases:

Infections

Infectious disease

< Previous: Overview

Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈